Eribulin Mesylate Patent Expiration
Eribulin Mesylate is Used for treating patients with metastatic breast cancer. It was first introduced by Eisai Inc
Eribulin Mesylate Patents
Given below is the list of patents protecting Eribulin Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Halaven |
USRE46965 (Pediatric) | Intermediates for the preparation of analogs of Halichondrin B | Jul 08, 2027 | Eisai Inc |
| Halaven | USRE46965 | Intermediates for the preparation of analogs of Halichondrin B | Jan 08, 2027 | Eisai Inc |
| Halaven |
US6214865 (Pediatric) | Macrocyclic analogs and methods of their use and preparation |
Jan 20, 2024
(Expired) | Eisai Inc |
| Halaven | US8097648 | Methods and compositions for use in treating cancer |
Jan 22, 2021
(Expired) | Eisai Inc |
| Halaven | US6214865 | Macrocyclic analogs and methods of their use and preparation |
Jun 16, 2019
(Expired) | Eisai Inc |
| Halaven | US6469182 | Intermediates in the preparation of macrocyclic analogs |
Jun 16, 2019
(Expired) | Eisai Inc |
| Halaven | US7470720 | Methods and compositions for use in treating cancer |
Jun 16, 2019
(Expired) | Eisai Inc |
Eribulin Mesylate's Family Patents
Explore Our Curated Drug Screens
Eribulin Mesylate Generic API Manufacturers
Several generic applications have been filed for Eribulin Mesylate. The first generic version for Eribulin Mesylate was by Gland Pharma Ltd and was approved on Apr 5, 2024. And the latest generic version is by Chia Tai Tianqing Pharmaceutical Group Co Ltd and was approved on Mar 4, 2025.
Given below is the list of companies who have filed for Eribulin Mesylate generic, along with the locations of their manufacturing plants worldwide.
1. BAXTER HLTHCARE CORP
Baxter Healthcare Corp has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Baxter Hlthcare Corp.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/2ML (0.5MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 1, 2024 |
2. CHIA TAI TIANQING
Chia Tai Tianqing Pharmaceutical Group Co Ltd has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Chia Tai Tianqing.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/2ML (0.5MG/ML) | solution | Prescription | INTRAVENOUS | AP | Mar 4, 2025 |
Manufacturing Plant Locations New
Chia Tai Tianqing's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Chia Tai Tianqing as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| China |
| |||
3. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/2ML (0.5MG/ML) | solution | Prescription | INTRAVENOUS | AP | Apr 5, 2024 |
4. JIANGXI QINGFENG
Jiangxi Qingfeng Pharmaceutical Co Ltd has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Jiangxi Qingfeng.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/2ML (0.5MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jun 28, 2024 |
5. LONG GROVE PHARMS
Long Grove Pharmaceuticals Llc has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Long Grove Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/2ML (0.5MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jul 18, 2024 |